Alzex Neuropharma Inc.
TRRI
$0.00
-$0.07-99.58%
OTC PK
| 06/30/2011 | 03/31/2011 | 12/31/2010 | 09/30/2010 | 06/30/2010 | |
|---|---|---|---|---|---|
| Net Income | -54.70K | -37.60K | 203.00K | -15.10K | -32.50K |
| Total Depreciation and Amortization | 28.10K | 27.00K | 35.50K | 2.70K | 29.80K |
| Total Amortization of Deferred Charges | -- | -- | -54.10K | 27.00K | -- |
| Total Other Non-Cash Items | 71.80K | -55.00K | 44.30K | 0.00 | 15.20K |
| Change in Net Operating Assets | 190.30K | 21.60K | -88.40K | -16.00K | -117.90K |
| Cash from Operations | 235.50K | -43.90K | 140.40K | -1.30K | -105.50K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 48.40K | 93.20K | -108.20K | -- | 153.70K |
| Total Debt Repaid | -236.00K | -38.00K | 141.30K | -78.50K | -97.90K |
| Issuance of Common Stock | -- | -- | -- | 82.50K | -- |
| Repurchase of Common Stock | -- | -- | -82.50K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -44.10K | -- | -- |
| Cash from Financing | -187.60K | 55.20K | -93.50K | 4.00K | 55.80K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | 0.00 | 0.00 | -- |
| Net Change in Cash | 47.90K | 11.30K | 46.90K | 2.70K | -49.70K |